Contrasting Embecta (NASDAQ:EMBC) & Biocorrx (OTCMKTS:BICX)

Embecta (NASDAQ:EMBC) and Biocorrx (OTCMKTS:BICX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Earnings and Valuation

This table compares Embecta and Biocorrx”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08 billion	0.19	$95.40 million	$1.90	1.83
Biocorrx	$800,000.00	12.54	-$3.44 million	($0.16)	-2.13

Embecta has higher revenue and earnings than Biocorrx. Biocorrx is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Embecta and Biocorrx, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	3	2	0	0	1.40
Biocorrx	0	1	0	0	2.00

Embecta presently has a consensus price target of $11.00, suggesting a potential upside of 215.82%. Given Embecta’s higher probable upside, research analysts plainly believe Embecta is more favorable than Biocorrx.

Profitability

This table compares Embecta and Biocorrx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Embecta	10.73%	-23.96%	14.12%
Biocorrx	N/A	N/A	-73.40%

Risk & Volatility

Embecta has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Biocorrx has a beta of 0.16, meaning that its share price is 84% less volatile than the S&P 500.

Insider & Institutional Ownership

93.8% of Embecta shares are held by institutional investors. 1.3% of Embecta shares are held by company insiders. Comparatively, 21.4% of Biocorrx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Embecta beats Biocorrx on 9 of the 13 factors compared between the two stocks.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

About Biocorrx

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.